Scientific Reports: 缺血预处理联合远程缺血预处理对肝移植术后缺血再灌注损伤的影响

2019-01-20 MedSci MedSci原创

缺血预处理(IPC)和远程缺血预处理(RIPer)能够给予肝脏缺血再灌注损伤(IRI)后的保护作用,但是RIPer应用于肝移植的数据目前还十分有限。本研究旨在评估IPC和RIPer的组合是否提供更强的保护作用。

背景:
缺血预处理(IPC)和远程缺血预处理(RIPer)能够给予肝脏缺血再灌注损伤(IRI)后的保护作用,但是RIPer应用于肝移植的数据目前还十分有限。本研究旨在评估IPC和RIPer的组合是否提供更强的保护作用。

方法:
研究人员将C57BL / 6小鼠(160对)分为4组:对照组,仅进行肝移植; IPC,供体肺门夹紧10分钟,然后再灌注15分钟; RIPer,再灌注前进行3次股骨血管束闭塞(5 min)和开放(5 min); 以及 IPC + RIPer组。然后处死小鼠获得肝组织用于组织学评估,TUNEL染色, GSH-Px测定,和NF-κBp65蛋白和Bcl-2 / Bax mRNA分析。血样本用于评估ALT,AST,TNF-α,NOx水平和流式细胞术。

结果:
研究人员发现RIPer组的小鼠在术后2小时的ALT,TNF-α,GSH-Px和NOx的保护作用小于IPC,但在术后24小时和72小时几乎相当,并且除了ALT,Bcl-2 / Bax mRNA的指标外,其他指标均显示联合治疗与单一治疗相比有更强的保护作用。

结论:
本研究提出了一种新的治疗策略,可以增强临床肝移植中对IRI的保护作用。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1763592, encodeId=23941e63592a1, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Fri Nov 01 14:19:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998954, encodeId=b1e01998954fd, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 15 19:19:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375912, encodeId=504413e59125e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397702, encodeId=4b71139e7025a, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1763592, encodeId=23941e63592a1, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Fri Nov 01 14:19:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998954, encodeId=b1e01998954fd, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 15 19:19:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375912, encodeId=504413e59125e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397702, encodeId=4b71139e7025a, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1763592, encodeId=23941e63592a1, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Fri Nov 01 14:19:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998954, encodeId=b1e01998954fd, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 15 19:19:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375912, encodeId=504413e59125e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397702, encodeId=4b71139e7025a, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-01-22 jichang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1763592, encodeId=23941e63592a1, content=<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30647, encryptionId=8c323064e09, topicName=再灌注损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56da37541085, createdName=ms9833124466084992, createdTime=Fri Nov 01 14:19:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998954, encodeId=b1e01998954fd, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Feb 15 19:19:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375912, encodeId=504413e59125e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397702, encodeId=4b71139e7025a, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Tue Jan 22 06:19:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]

相关资讯

Stroke: 缺血性卒中后恶性脑水肿的早期预测模型

缺血性中风后如果发生恶性脑水肿那么患者的死亡率会很高。因此,早期预测恶性脑水肿的发生很重要,因此,本项研究中研究人员系统审查了目前现有的预测模型,以确定预测恶性水肿发生的可靠标志物。

Stroke: 内分泌调节因子rFGF21可以改善2型糖尿病小鼠局灶性缺血性卒中后的神经系统结局

中风的复杂性和异质性以及相关的合并症使神经保护药物在临床实践中效果不尽如人意。因此,针对特定患者亚组的靶向治疗的发展已成为中风研究中的新型治疗方向。患有2型糖尿病的缺血性中风具有几乎两倍的死亡率和更差的神经学结果。在本研究中,研究人员测试rFGF21(重组人成纤维细胞生长因子21)给药对于改善2型糖尿病的缺血性卒中的神经学结果的情况。

Stroke: 颈椎动脉夹层血栓切除术治疗急性缺血性卒中的可行性

颈椎动脉夹层引起的急性缺血性卒中即使采用适当的药物治疗也往往会导致不良后果。本研究评估了血管内血栓切除术治疗与颈动脉夹层相关的急性缺血性卒中的安全性和有效性。

Stroke: 血凝块迁移与急性缺血性卒中患者静脉溶栓相关

在临床工作中研究人员发现在出现急性大血管闭塞的患者中有凝块迁移至远端颅内动脉段的现象。据推测,患者接受静脉溶栓(IVT)会增加凝块迁移的风险,并且血管内血栓切除术(EVT)会导致血栓移动。这项研究的目的是调查EVT前凝块迁移的发生率及其与IVT的关系。